Postmarketing PowerPoint PPT Presentations

All Time
Show:
Recommended
Sort by:
Device Postmarket Studies PowerPoint PPT Presentation
Device Postmarket Studies - Device Postmarket Studies. Danica Marinac-Dabic, MD, PhD. Chief, Epidemiology Branch ... Longer-term performance including effects of re-treatments & product changes ...
Device Postmarket Studies. Danica Marinac-Dabic, MD, PhD. Chief, Epidemiology Branch ... Longer-term performance including effects of re-treatments & product changes ...
| PowerPoint PPT presentation | free to view
Postmarket Surveillance of Medical Device Adverse Events PowerPoint PPT Presentation
Postmarket Surveillance of Medical Device Adverse Events - Postmarket Surveillance of Medical Device Adverse Events Hesha Jani Duggirala, PhD Epidemiology Branch Division of Postmarket Surveillance Office of Surveillance and ...
Postmarket Surveillance of Medical Device Adverse Events Hesha Jani Duggirala, PhD Epidemiology Branch Division of Postmarket Surveillance Office of Surveillance and ...
| PowerPoint PPT presentation | free to view
POSTMARKETING SAFETY STUDIES PowerPoint PPT Presentation
POSTMARKETING SAFETY STUDIES - Public health burden of serious adverse drug events. Reactions to our drug ... Phase 1 Studies: Drug cautiously given to small group of healthy volunteers ...
Public health burden of serious adverse drug events. Reactions to our drug ... Phase 1 Studies: Drug cautiously given to small group of healthy volunteers ...
| PowerPoint PPT presentation | free to view
Postmarket Surveillance of Medical Device Adverse Events PowerPoint PPT Presentation
Postmarket Surveillance of Medical Device Adverse Events - Division of Postmarket Surveillance. Office of Surveillance ... Center for Devices and Radiological Health ... Device death, serious injuries, and malfunctions ...
Division of Postmarket Surveillance. Office of Surveillance ... Center for Devices and Radiological Health ... Device death, serious injuries, and malfunctions ...
| PowerPoint PPT presentation | free to view
Trends in Postmarket Surveillance PowerPoint PPT Presentation
Trends in Postmarket Surveillance - the effect of user fees on FDA's ability to conduct postmarket surveillance ... Dodd has record on pediatric FDA issues ... MDUFMA | Other Policies ...
the effect of user fees on FDA's ability to conduct postmarket surveillance ... Dodd has record on pediatric FDA issues ... MDUFMA | Other Policies ...
| PowerPoint PPT presentation | free to view
Best Practices in Meeting Your Postmarketing Study Commitments PowerPoint PPT Presentation
Best Practices in Meeting Your Postmarketing Study Commitments - Best Practices in Meeting Your Postmarketing Study Commitments. Cyndi Verst-Brasch, Pharm.D., M.S. ... N o r t h A m e r I c a E u r o p e A s I a / P a c I ...
Best Practices in Meeting Your Postmarketing Study Commitments. Cyndi Verst-Brasch, Pharm.D., M.S. ... N o r t h A m e r I c a E u r o p e A s I a / P a c I ...
| PowerPoint PPT presentation | free to download
Postmarketing Studies: OND Perspective PowerPoint PPT Presentation
Postmarketing Studies: OND Perspective - Sponsor voluntarily commits to conducting study(ies) after approval ... of a New Product Application and Preparing a Report on the Review, February 2005 ...
Sponsor voluntarily commits to conducting study(ies) after approval ... of a New Product Application and Preparing a Report on the Review, February 2005 ...
| PowerPoint PPT presentation | free to download
Postmarketing Safety Data PowerPoint PPT Presentation
Postmarketing Safety Data - The patient was without symptoms until the next afternoon when the patient's ... Sonography 'there were no congested bile ducts and the liver was morphological ...
The patient was without symptoms until the next afternoon when the patient's ... Sonography 'there were no congested bile ducts and the liver was morphological ...
| PowerPoint PPT presentation | free to view
Causality Assessment in postmarketing adverse events PowerPoint PPT Presentation
Causality Assessment in postmarketing adverse events - Examples of methods of assessment- WHO Index cases, PRR, ... Factors to judge (Lane and Hutchison , 1986) Repeatability. Explicitness. Explanatory culpability ...
Examples of methods of assessment- WHO Index cases, PRR, ... Factors to judge (Lane and Hutchison , 1986) Repeatability. Explicitness. Explanatory culpability ...
| PowerPoint PPT presentation | free to view
Vaccine Safety Evaluation: Postmarketing Surveillance Conference PowerPoint PPT Presentation
Vaccine Safety Evaluation: Postmarketing Surveillance Conference - Meningococcal disease isolate serogroup and dominant subtype 1990 -2005 ... e.g. all intensive care admissions within 7 days/ unusual events thought to be ...
Meningococcal disease isolate serogroup and dominant subtype 1990 -2005 ... e.g. all intensive care admissions within 7 days/ unusual events thought to be ...
| PowerPoint PPT presentation | free to view
Risk analysis and postmarketing pharmacovigilance activities PowerPoint PPT Presentation
Risk analysis and postmarketing pharmacovigilance activities - Boehringer Ingelheim (Pty) Ltd. Acknowledgement & thanks: ... The Lancet starts collecting notifications of side effects after a death caused by anaesthesia ...
Boehringer Ingelheim (Pty) Ltd. Acknowledgement & thanks: ... The Lancet starts collecting notifications of side effects after a death caused by anaesthesia ...
| PowerPoint PPT presentation | free to view
PostMarketing AE Reports of Topical Calcineurin Inhibitors PowerPoint PPT Presentation
PostMarketing AE Reports of Topical Calcineurin Inhibitors - Pediatric Advisory Subcommittee of the Anti-Infective Drugs Advisory Committee ... Eczema herpeticum infected eyes, Scarlatina, Soft tissue infection, Staph ...
Pediatric Advisory Subcommittee of the Anti-Infective Drugs Advisory Committee ... Eczema herpeticum infected eyes, Scarlatina, Soft tissue infection, Staph ...
| PowerPoint PPT presentation | free to view
Macrolide Antibiotics and Torsade de Pointes Postmarketing Analysis PowerPoint PPT Presentation
Macrolide Antibiotics and Torsade de Pointes Postmarketing Analysis - Iatrogenic QT Prolongation and Torsade de Pointes. Adverse Events in the ... Recognition of the potential for Torsade de Pointes should clearly be acknowledged. ...
Iatrogenic QT Prolongation and Torsade de Pointes. Adverse Events in the ... Recognition of the potential for Torsade de Pointes should clearly be acknowledged. ...
| PowerPoint PPT presentation | free to view
CAMPATH alemtuzumab: Status of Phase IV Postmarketing Commitments PowerPoint PPT Presentation
CAMPATH alemtuzumab: Status of Phase IV Postmarketing Commitments - Stephen Eckert, Ph.D. Senior Director, Biostatistics. Mark Goldberg, M.D. Senior Vice President, Clinical Research. Mark Hayes, Ph.D. Vice President, ...
Stephen Eckert, Ph.D. Senior Director, Biostatistics. Mark Goldberg, M.D. Senior Vice President, Clinical Research. Mark Hayes, Ph.D. Vice President, ...
| PowerPoint PPT presentation | free to view
The FDAs Postmarketing Adverse Drug Experience Inspectional Program PowerPoint PPT Presentation
The FDAs Postmarketing Adverse Drug Experience Inspectional Program - ... 15 calendar days if Serious and Unexpected (domestic and foreign) Follow-up information. Non-applicant notifies applicant within five calendar days. 8. Periodic ...
... 15 calendar days if Serious and Unexpected (domestic and foreign) Follow-up information. Non-applicant notifies applicant within five calendar days. 8. Periodic ...
| PowerPoint PPT presentation | free to view
Postmarket Transformation at CDRH: The Role of Statistician PowerPoint PPT Presentation
Postmarket Transformation at CDRH: The Role of Statistician - Danica Marinac Dabic, M.D., Ph.D. Chief, Epidemiology Branch ... CDRH postmarket responsibilities and challenges. Established roles of the CDRH statisticians ...
Danica Marinac Dabic, M.D., Ph.D. Chief, Epidemiology Branch ... CDRH postmarket responsibilities and challenges. Established roles of the CDRH statisticians ...
| PowerPoint PPT presentation | free to view
Using the FDA’s Adverse Event Reporting System (AERS) in Postmarketing Surveillance PowerPoint PPT Presentation
Using the FDA’s Adverse Event Reporting System (AERS) in Postmarketing Surveillance - Using the FDA s Adverse Event Reporting System (AERS) in Postmarketing Surveillance Joyce P. Weaver, Pharm.D., BCPS Division of Drug Risk Evaluation
Using the FDA s Adverse Event Reporting System (AERS) in Postmarketing Surveillance Joyce P. Weaver, Pharm.D., BCPS Division of Drug Risk Evaluation
| PowerPoint PPT presentation | free to view
Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate PowerPoint PPT Presentation
Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate - Title: Postmarketing Surveillance and Pharmacovigilance Practice in FDA Author: CDER.USER Last modified by: FDA User Created Date: 9/18/2003 4:06:40 PM
Title: Postmarketing Surveillance and Pharmacovigilance Practice in FDA Author: CDER.USER Last modified by: FDA User Created Date: 9/18/2003 4:06:40 PM
| PowerPoint PPT presentation | free to view
Overview of Postmarketing Safety Surveillance in FDA For Drugs and Biologics PowerPoint PPT Presentation
Overview of Postmarketing Safety Surveillance in FDA For Drugs and Biologics - OTC drugs - No reporting requirement unless drug was approved under NDA ... Congress, GAO, DHHS, FBI, CPSC, foreign regulatory authorities. Develop risk ...
OTC drugs - No reporting requirement unless drug was approved under NDA ... Congress, GAO, DHHS, FBI, CPSC, foreign regulatory authorities. Develop risk ...
| PowerPoint PPT presentation | free to view
Kineret anakinra: A Review of Safety Data Postmarketing Surveillance PowerPoint PPT Presentation
Kineret anakinra: A Review of Safety Data Postmarketing Surveillance - Pneumonia: 8 serious cases reported, 2 of which were fatal ... serious ISR on the thigh, with systemic symptoms (hypotension and tachycardia) ...
Pneumonia: 8 serious cases reported, 2 of which were fatal ... serious ISR on the thigh, with systemic symptoms (hypotension and tachycardia) ...
| PowerPoint PPT presentation | free to view
Postmarketing Surveillance Conference PowerPoint PPT Presentation
Postmarketing Surveillance Conference - ... of State and Territorial Epidemiologists (CSTE) participated in active GBS surveillance. State epidemiologists and Emerging Infectious Disease specialists in ...
... of State and Territorial Epidemiologists (CSTE) participated in active GBS surveillance. State epidemiologists and Emerging Infectious Disease specialists in ...
| PowerPoint PPT presentation | free to view
Discussion of a PostMarketing Approval Study for 30day Continuous Wear Contact Lenses PowerPoint PPT Presentation
Discussion of a PostMarketing Approval Study for 30day Continuous Wear Contact Lenses - Discussion of a Post-Marketing Approval Study for 30-day Continuous Wear Contact Lenses ... until 30-day lenses have sufficient market share. ...
Discussion of a Post-Marketing Approval Study for 30-day Continuous Wear Contact Lenses ... until 30-day lenses have sufficient market share. ...
| PowerPoint PPT presentation | free to view
Topical Corticosteroid Adverse Events in Pediatric Patients Analysis of Postmarketing Reports PowerPoint PPT Presentation
Topical Corticosteroid Adverse Events in Pediatric Patients Analysis of Postmarketing Reports - Topical Corticosteroid Adverse Events in Pediatric Patients Analysis of Postmarketing Reports Pediatric Advisory Subcommittee of the Anti-Infective Drugs Advisory ...
Topical Corticosteroid Adverse Events in Pediatric Patients Analysis of Postmarketing Reports Pediatric Advisory Subcommittee of the Anti-Infective Drugs Advisory ...
| PowerPoint PPT presentation | free to view
HCOL Health Care Online, Inc' Services and Software for Clinical Trials and PostMarketing Studies' PowerPoint PPT Presentation
HCOL Health Care Online, Inc' Services and Software for Clinical Trials and PostMarketing Studies' - The investigational site staff enters necessary data and details of the treatment. ... Help your investigational sites be more compliant. Health Care Online ...
The investigational site staff enters necessary data and details of the treatment. ... Help your investigational sites be more compliant. Health Care Online ...
| PowerPoint PPT presentation | free to view
Active postmarketing surveillance for vaccine adverse events: The experience of the Vaccine Safety D PowerPoint PPT Presentation
Active postmarketing surveillance for vaccine adverse events: The experience of the Vaccine Safety D - Why we need active post-marketing surveillance ... Known biologic properties of the vaccine. VAERS reports. Literature on this or similar vaccines ...
Why we need active post-marketing surveillance ... Known biologic properties of the vaccine. VAERS reports. Literature on this or similar vaccines ...
| PowerPoint PPT presentation | free to view
PostMarketing Safety Information on Medical Products: Potentials for Improvements PowerPoint PPT Presentation
PostMarketing Safety Information on Medical Products: Potentials for Improvements - The views expressed are those of the author, and do not represent an official FDA ... EMRs. Compatability' of data needs with data sources. Richness of detail ...
The views expressed are those of the author, and do not represent an official FDA ... EMRs. Compatability' of data needs with data sources. Richness of detail ...
| PowerPoint PPT presentation | free to view
Medical Device Registries: Multiple Applications PowerPoint PPT Presentation
Medical Device Registries: Multiple Applications - Medical Device Registries: Multiple Applications Thomas P. Gross, MD, MPH Director Division of Postmarket Surveillance Office of Surveillance & Biometrics
Medical Device Registries: Multiple Applications Thomas P. Gross, MD, MPH Director Division of Postmarket Surveillance Office of Surveillance & Biometrics
| PowerPoint PPT presentation | free to download
Global%20Harmonization%20of%20Medical%20Device%20Regulation:%20Accomplishments,%20Challenges%20and%20Opportunities PowerPoint PPT Presentation
Global%20Harmonization%20of%20Medical%20Device%20Regulation:%20Accomplishments,%20Challenges%20and%20Opportunities - Essential principles conformance vs. review. Postmarket surveillance ... Public declaration vs. de facto practice. Industry must get engaged ...
Essential principles conformance vs. review. Postmarket surveillance ... Public declaration vs. de facto practice. Industry must get engaged ...
| PowerPoint PPT presentation | free to download
Zelnorm PowerPoint PPT Presentation
Zelnorm - Review Zelnorm Phase III clinical trial information. Review postmarketing safety data ... Introduction (continued) John Cutt, PhD. Activity of tegaserod in GI tract ...
Review Zelnorm Phase III clinical trial information. Review postmarketing safety data ... Introduction (continued) John Cutt, PhD. Activity of tegaserod in GI tract ...
| PowerPoint PPT presentation | free to download
Panel questions PowerPoint PPT Presentation
Panel questions - Panel questions Reproduction and teratogenicity Tumorogenicity Radiographic effectiveness Instructions for use Postmarket studies Reproduction and teratogenicity ...
Panel questions Reproduction and teratogenicity Tumorogenicity Radiographic effectiveness Instructions for use Postmarket studies Reproduction and teratogenicity ...
| PowerPoint PPT presentation | free to view
FDLI Introduction to Medical Device Law and Regulation PowerPoint PPT Presentation
FDLI Introduction to Medical Device Law and Regulation - FDLI Introduction to Medical Device Law and Regulation. Other Postmarket Controls ... Not just representations made or suggested, but also material omissions. 19 ...
FDLI Introduction to Medical Device Law and Regulation. Other Postmarket Controls ... Not just representations made or suggested, but also material omissions. 19 ...
| PowerPoint PPT presentation | free to download
Statement before the Food and Drug Administration Public Hearing on Prescription Drug User Fee Act P PowerPoint PPT Presentation
Statement before the Food and Drug Administration Public Hearing on Prescription Drug User Fee Act P - Made a significant contribution in securing financial resources ... Polypharmacy. Off label uses. Shared Responsibility for Postmarket Surveillance. Manufacturers ...
Made a significant contribution in securing financial resources ... Polypharmacy. Off label uses. Shared Responsibility for Postmarket Surveillance. Manufacturers ...
| PowerPoint PPT presentation | free to view
Psychiatric Adverse Events with Drug Treatments of ADHD PowerPoint PPT Presentation
Psychiatric Adverse Events with Drug Treatments of ADHD - Psychiatric Adverse Events with Drug Treatments of ADHD Review of Postmarketing Safety Data: Pediatric Population Kate Gelperin, M.D., M.P.H. FDA Office of Drug Safety
Psychiatric Adverse Events with Drug Treatments of ADHD Review of Postmarketing Safety Data: Pediatric Population Kate Gelperin, M.D., M.P.H. FDA Office of Drug Safety
| PowerPoint PPT presentation | free to view
Summary Recommendations to FDA PowerPoint PPT Presentation
Summary Recommendations to FDA - Summary Recommendations to FDA. Society of Thoracic Surgeons' Perspective ... FDA, as part of their Postmarket Transformation, should develop data ...
Summary Recommendations to FDA. Society of Thoracic Surgeons' Perspective ... FDA, as part of their Postmarket Transformation, should develop data ...
| PowerPoint PPT presentation | free to view
Can modafinil cause mental trips?
Can modafinil cause mental trips? - Mental antagonistic encounters have been accounted for in patients treated with modafinil. Postmarketing antagonistic occasions related to the utilization of modafinil have included lunacy.
Mental antagonistic encounters have been accounted for in patients treated with modafinil. Postmarketing antagonistic occasions related to the utilization of modafinil have included lunacy.
Risk%20Management,%20Risk%20Communication,%20and%20Drug%20Safety:%20The%20U.S.%20Experience PowerPoint PPT Presentation
Risk%20Management,%20Risk%20Communication,%20and%20Drug%20Safety:%20The%20U.S.%20Experience - FDA lacks authority and funding for adequate oversight of drug safety ... FDA imprimatur on unvalidated safety information. Potential for confusion, overreaction ...
FDA lacks authority and funding for adequate oversight of drug safety ... FDA imprimatur on unvalidated safety information. Potential for confusion, overreaction ...
| PowerPoint PPT presentation | free to download
Critical Path Research: Getting New Technology from Bench to Bedside A Device Perspective FDA Science Board November 5, 2004 PowerPoint PPT Presentation
Critical Path Research: Getting New Technology from Bench to Bedside A Device Perspective FDA Science Board November 5, 2004 - Dun and Bradstreet FY 04 data shows the device industry grew from 13,579 to 14, ... and partnerships for evaluating new technology based on sound science in a ...
Dun and Bradstreet FY 04 data shows the device industry grew from 13,579 to 14, ... and partnerships for evaluating new technology based on sound science in a ...
| PowerPoint PPT presentation | free to view
CDRH Update Facilitating Medical Device Innovation and Technology PowerPoint PPT Presentation
CDRH Update Facilitating Medical Device Innovation and Technology - Medical Device User Fee and Modernization Act of 2002 (MDUFMA)
Medical Device User Fee and Modernization Act of 2002 (MDUFMA)
| PowerPoint PPT presentation | free to view
Alsheikh-Ali A et al. Circulation 2005; available at: http://circ.ahajournals.org. PowerPoint PPT Presentation
Alsheikh-Ali A et al. Circulation 2005; available at: http://circ.ahajournals.org. - Prescriptions (in millions) 315. 52. 381. 145. Adverse events (n) Atorvastatin. Pravastatin. Simvastatin. Rosuvastatin. Outcome ...
Prescriptions (in millions) 315. 52. 381. 145. Adverse events (n) Atorvastatin. Pravastatin. Simvastatin. Rosuvastatin. Outcome ...
| PowerPoint PPT presentation | free to download
Parallel Session 1 The Role of the Statistician in Post-Marketing, Including Surveillance PowerPoint PPT Presentation
Parallel Session 1 The Role of the Statistician in Post-Marketing, Including Surveillance - Provide insight into the role of the statistician in FDA post-marketing ... 8:20: Danica Marinac-Dabic, MD, PhD (Chief, Epidemiology Branch, OSB, CDRH) ...
Provide insight into the role of the statistician in FDA post-marketing ... 8:20: Danica Marinac-Dabic, MD, PhD (Chief, Epidemiology Branch, OSB, CDRH) ...
| PowerPoint PPT presentation | free to view
Unique Device Identification (UDI): Implementation and Adoption PowerPoint PPT Presentation
Unique Device Identification (UDI): Implementation and Adoption - Unique Device Identification (UDI): Implementation and Adoption Leslie M Tompkins, PhD FDA, Center for Devices and Radiological Health UDI Lead, Standards and ...
Unique Device Identification (UDI): Implementation and Adoption Leslie M Tompkins, PhD FDA, Center for Devices and Radiological Health UDI Lead, Standards and ...
| PowerPoint PPT presentation | free to download
Brian L. Strom, M.D., M.P.H. PowerPoint PPT Presentation
Brian L. Strom, M.D., M.P.H. - ... PharMark Corp, A.H. Robins Company, Rockefeller Foundation, ... SmithKline Beecham Pharmaceuticals, Whitehall-Robins Healthcare, and Wyeth-Ayerst Research ...
... PharMark Corp, A.H. Robins Company, Rockefeller Foundation, ... SmithKline Beecham Pharmaceuticals, Whitehall-Robins Healthcare, and Wyeth-Ayerst Research ...
| PowerPoint PPT presentation | free to view
CDRH: Minimizing Risk of TSE Agents in Medical Devices PowerPoint PPT Presentation
CDRH: Minimizing Risk of TSE Agents in Medical Devices - Neurological Devices/General Surgical Instruments. In Vitro Diagnostic Devices. 4 ... General Surgical instruments (scalpels, scissors, biopsy forceps, retractors) 8 ...
Neurological Devices/General Surgical Instruments. In Vitro Diagnostic Devices. 4 ... General Surgical instruments (scalpels, scissors, biopsy forceps, retractors) 8 ...
| PowerPoint PPT presentation | free to view
Parallel Session 1 Post Market Adverse Events: FDA Reporting Systems and Surveillance PowerPoint PPT Presentation
Parallel Session 1 Post Market Adverse Events: FDA Reporting Systems and Surveillance - Parallel Session 1 Post Market Adverse Events: FDA Reporting Systems and Surveillance
Parallel Session 1 Post Market Adverse Events: FDA Reporting Systems and Surveillance
| PowerPoint PPT presentation | free to view
Drug Quality and Safety: Comparison of EMEA and FDA Rules PowerPoint PPT Presentation
Drug Quality and Safety: Comparison of EMEA and FDA Rules - ... most products on the EU market were approved by Member State agencies. ... GMPs apply to Active Pharmaceutical Ingredients After Eprex and Chiron, ...
... most products on the EU market were approved by Member State agencies. ... GMPs apply to Active Pharmaceutical Ingredients After Eprex and Chiron, ...
| PowerPoint PPT presentation | free to download
How does the U.S. FDA Regulate Medical Devices? PowerPoint PPT Presentation
How does the U.S. FDA Regulate Medical Devices? - ... 34.00 6987.00 13.00 7225.00 4789.00 1284.00 556.00 6629.00 344.00 64.00 7037.00 188.00 46736.00 9077.00 8209.00 7242.00 24528.00 11284.00 4682.00 40494.00 6242 ...
... 34.00 6987.00 13.00 7225.00 4789.00 1284.00 556.00 6629.00 344.00 64.00 7037.00 188.00 46736.00 9077.00 8209.00 7242.00 24528.00 11284.00 4682.00 40494.00 6242 ...
| PowerPoint PPT presentation | free to view
Combination Products CBER Report PowerPoint PPT Presentation
Combination Products CBER Report - The Office will handle disputes involving timeliness, unless 'clearly premarket' 7 ... What is the true extent of this authority? 10. Office's Report to ...
The Office will handle disputes involving timeliness, unless 'clearly premarket' 7 ... What is the true extent of this authority? 10. Office's Report to ...
| PowerPoint PPT presentation | free to view
Critical Path Research: Getting New Technology from Bench to Bedside A Device Perspective FDA Science Board November 5, 2004 PowerPoint PPT Presentation
Critical Path Research: Getting New Technology from Bench to Bedside A Device Perspective FDA Science Board November 5, 2004 - Critical Path Research: Getting New Technology from Bench to Bedside A Device Perspective FDA Science Board November 5, 2004 Dan Schultz Director, CDRH
Critical Path Research: Getting New Technology from Bench to Bedside A Device Perspective FDA Science Board November 5, 2004 Dan Schultz Director, CDRH
| PowerPoint PPT presentation | free to view
The FDA PowerPoint PPT Presentation
The FDA - ... (domestic and foreign) Follow-up ... The Headquarter/Field Adverse Event Team The headquarters scientists use adverse event reports to evaluate the safety of ...
... (domestic and foreign) Follow-up ... The Headquarter/Field Adverse Event Team The headquarters scientists use adverse event reports to evaluate the safety of ...
| PowerPoint PPT presentation | free to view
Tumor Necrosis Factor Inhibitors Box Warnings PowerPoint PPT Presentation
Tumor Necrosis Factor Inhibitors Box Warnings - Tumor Necrosis Factor Inhibitors Box Warnings Nina Elk, Pharm.D. Internal Medicine Resident (PGY2) Kingsbrook Jewish Medical Center Department of Pharmacy
Tumor Necrosis Factor Inhibitors Box Warnings Nina Elk, Pharm.D. Internal Medicine Resident (PGY2) Kingsbrook Jewish Medical Center Department of Pharmacy
| PowerPoint PPT presentation | free to view
Pharmaceutical Regulatory Affairs: Discovery to Approval PowerPoint PPT Presentation
Pharmaceutical Regulatory Affairs: Discovery to Approval - Pharmaceutical Regulatory Affairs: Discovery to Approval R. Sam Niedbala, Ph.D. (SAN204@Lehigh.edu) Lecture 7 House Keeping Items House Keeping Items Lecture 7 FDA ...
Pharmaceutical Regulatory Affairs: Discovery to Approval R. Sam Niedbala, Ph.D. (SAN204@Lehigh.edu) Lecture 7 House Keeping Items House Keeping Items Lecture 7 FDA ...
| PowerPoint PPT presentation | free to view
Review of post-marketing safety of Factive (gemifloxacin) PowerPoint PPT Presentation
Review of post-marketing safety of Factive (gemifloxacin) - Stevens-Johnson syndrome (SJS) Toxic epidermal necrolysis (TEN) ... Evelyn R. Farinas, R.Ph., M.G.A.. Melissa Truffa, R.Ph. Syed Rizwanuddin Ahmad, M.D., M.P.H. ...
Stevens-Johnson syndrome (SJS) Toxic epidermal necrolysis (TEN) ... Evelyn R. Farinas, R.Ph., M.G.A.. Melissa Truffa, R.Ph. Syed Rizwanuddin Ahmad, M.D., M.P.H. ...
| PowerPoint PPT presentation | free to view
Core Concepts in Pharmacology PowerPoint PPT Presentation
Core Concepts in Pharmacology - Stages of Therapeutic and Biologic Drug Approval. Preclinical investigation ... Recent Changes to Drug Approval Process. Prescription Drug User Fee Act. FDA ...
Stages of Therapeutic and Biologic Drug Approval. Preclinical investigation ... Recent Changes to Drug Approval Process. Prescription Drug User Fee Act. FDA ...
| PowerPoint PPT presentation | free to view
Safety PowerPoint PPT Presentation
Safety - Safety & Efficacy Update on Approved TNF-Blocking Agents. Jeffrey N. Siegel, M.D. ... Improving signs and symptoms. Inhibition of progression of structural damage ...
Safety & Efficacy Update on Approved TNF-Blocking Agents. Jeffrey N. Siegel, M.D. ... Improving signs and symptoms. Inhibition of progression of structural damage ...
| PowerPoint PPT presentation | free to view
Droperidol Since 2001 FDA Risk Assessment PowerPoint PPT Presentation
Droperidol Since 2001 FDA Risk Assessment - Droperidol - revised data sheet : cardiac arrhythmias. France. ... Meds: Gent/Vanco, fent 550 mg total, versed 4mg total, KCl 40mEq, heparin 3000U IV ...
Droperidol - revised data sheet : cardiac arrhythmias. France. ... Meds: Gent/Vanco, fent 550 mg total, versed 4mg total, KCl 40mEq, heparin 3000U IV ...
| PowerPoint PPT presentation | free to download


Home About Us Terms and Conditions Privacy Policy Contact Us
Copyright 2024 CrystalGraphics, Inc. — All rights Reserved. PowerShow.com is a trademark of CrystalGraphics, Inc.
postmarketing — Search results on PowerShow.com